Skip to main content

Table 5 Multiple linear regression with TLR7 and TLR9 expressions as independent variables in lupus patients

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

Risk factors Adjusted coefficient (95%) P-value Adjusted R2
TLR7 level    0.592
HPV infection -0.815 (-6.827 to -1.751) 0.002  
Cumulative dose of prednisolone in the past 15 years, gm -0.356 (-0.014 to -0.001) 0.026  
High-risk HPV infection 0.217 (-1.487 to 3.926) 0.359  
Hydroxychloroquine therapy ever 0.012 (-1.919 to 2.046) 0.067  
TLR9 level    0.391
HPV infection -0.313 (-10.395 to -1.170) 0.015  
SLEDAI 0.474 (0.841 to 2.576) < 0.001  
Cumulative dose of hydroxychloroquine in the past 15 years, gm -0.268 (-0.012 to 0.000) 0.041  
Duration receiving treatment of Azathioprine, month -0.047 (-0.059 to 0.040) 0.706  
  1. HPV, human papillomavirus; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; TLR, toll-like receptor